The opening quarter of 2026 brought a noticeable cooling in mid-market life sciences venture activity. PitchBook data tracking U.S. life sciences venture rounds in the $5–20 million range shows just 65 deals representing $608.6 million of capital invested in Q1 2026. That marks a meaningful pullback from Q1 2025, which saw 87 deals and $868.5 million, and from Q1 2024, which produced 76 deals and $733.1 million in aggregate investment. Average capital per deal has held relatively steady, with roughly $9.4 million in Q1 2026 against $10.0 million in Q1 2025 and $9.6 million in Q1 2024, suggesting the slowdown is being driven by deal volume rather than check size. The context matters: the market recorded 359 deals and $3.75 billion of capital invested in 2025, modestly ahead of 339 deals and $3.48 billion in 2024. Because 2025 was a year of measured growth rather than decline, the Q1 2026 pullback does not simply extend an existing downturn. It instead suggests a potential inflection point that merits close attention in the quarters ahead.

Alongside these shifts in volume, three deal-term trends are reshaping how life sciences rounds at the $5-20 million size are negotiated and completed. Pay-to-play provisions are resurfacing, with lead investors pressing existing holders to fund their pro rata portion or face punitive recapitalizations that cut back existing preferential rights, a clear signal that leverage has shifted back to capital providers. Inside rounds and heavy insider participation have become increasingly common, keeping companies funded but removing arm's-length price discovery and raising conflict-of-interest issues that boards must address through appropriate procedural protections. Fundraising cycles are also stretching, with bridge rounds sized for longer runway and formal extension rounds a more common feature of the landscape. Founders and investors should be prepared for longer cycles, tougher terms, and more deliberate capital decisions.